BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30813708)

  • 1. Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma.
    Salama A; Arafa M; ElZahaf E; Shebl AM; Awad AAE; Ashamallah SA; Hemida R; Gamal A; Foda AA; Zalata K; Abdel-Hady EM
    J Pathol Transl Med; 2019 May; 53(3):164-172. PubMed ID: 30813708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
    Yu CG; Jiang XY; Li B; Gan L; Huang JF
    Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M; Zhao L; Shen D; Li X; Wang J; Wei L
    Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selected immunohistochemical prognostic factors in endometrial cancer.
    Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
    Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
    Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
    Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
    Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers.
    Weinberger V; Bednarikova M; Hausnerova J; Ovesna P; Vinklerova P; Minar L; Felsinger M; Jandakova E; Cihalova M; Zikan M
    Front Oncol; 2019; 9():265. PubMed ID: 31032226
    [No Abstract]   [Full Text] [Related]  

  • 12. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
    Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
    Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphovascular space invasion and cervical stromal invasion are independent risk factors for nodal metastasis in endometrioid endometrial cancer.
    Solmaz U; Mat E; Dereli M; Turan V; Gungorduk K; Hasdemir P; Tosun G; Dogan A; Ozdemir A; Adiyeke M; Sanci M
    Aust N Z J Obstet Gynaecol; 2015 Feb; 55(1):81-6. PubMed ID: 25688821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study.
    Naik PS; Deshmukh S; Khandeparkar SG; Joshi A; Babanagare S; Potdar J; Risbud NS
    J Midlife Health; 2015; 6(4):178-83. PubMed ID: 26903759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer.
    Wang C; Tran DA; Fu MZ; Chen W; Fu SW; Li X
    J Cancer; 2020; 11(7):1693-1701. PubMed ID: 32194781
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for paraaortic lymph node metastasis in endometrial cancer.
    Sari ME; Yalcin İ; Sahin H; Meydanli MM; Gungor T
    Int J Clin Oncol; 2017 Oct; 22(5):937-944. PubMed ID: 28523533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Expression Patterns of PTEN in Cyclic, Hyperplastic and Malignant Endometrium: Its Relation with ER, PR and Clinicopathological Parameters.
    Abd El-Maqsoud NM; El-Gelany S
    J Egypt Natl Canc Inst; 2009 Dec; 21(4):323-31. PubMed ID: 21415869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.